These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
407 related articles for article (PubMed ID: 10686191)
1. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Albano C; Felberbaum RE; Smitz J; Riethmüller-Winzen H; Engel J; Diedrich K; Devroey P Hum Reprod; 2000 Mar; 15(3):526-31. PubMed ID: 10686191 [TBL] [Abstract][Full Text] [Related]
2. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation. Rongières-Bertrand C; Olivennes F; Righini C; Fanchin R; Taïeb J; Hamamah S; Bouchard P; Frydman R Hum Reprod; 1999 Mar; 14(3):683-8. PubMed ID: 10221695 [TBL] [Abstract][Full Text] [Related]
3. Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction. Ludwig M; Felberbaum RE; Devroey P; Albano C; Riethmüller-Winzen H; Schüler A; Engel W; Diedrich K Arch Gynecol Obstet; 2000 Jul; 264(1):29-32. PubMed ID: 10985616 [TBL] [Abstract][Full Text] [Related]
4. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. Borm G; Mannaerts B Hum Reprod; 2000 Jul; 15(7):1490-8. PubMed ID: 10875855 [TBL] [Abstract][Full Text] [Related]
5. Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study. Felberbaum RE; Albano C; Ludwig M; Riethmüller-Winzen H; Grigat M; Devroey P; Diedrich K Hum Reprod; 2000 May; 15(5):1015-20. PubMed ID: 10783344 [TBL] [Abstract][Full Text] [Related]
6. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966 [TBL] [Abstract][Full Text] [Related]
7. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Olivennes F; Belaisch-Allart J; Emperaire JC; Dechaud H; Alvarez S; Moreau L; Nicollet B; Zorn JR; Bouchard P; Frydman R Fertil Steril; 2000 Feb; 73(2):314-20. PubMed ID: 10685535 [TBL] [Abstract][Full Text] [Related]
8. Subtle progesterone rise in the single-dose gonadotropin-releasing hormone antagonist (cetrorelix) stimulation protocol in patients undergoing in vitro fertilization or intracytoplasmic sperm injection cycles. Seow KM; Lin YH; Huang LW; Hsieh BC; Huang SC; Chen CY; Chen PH; Tzeng CR; Hwang JL Gynecol Endocrinol; 2007 Jun; 23(6):338-42. PubMed ID: 17616858 [TBL] [Abstract][Full Text] [Related]
9. Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization/intracytoplasmic sperm injection cycles. Albano C; Smitz J; Tournaye H; Riethmüller-Winzen H; Van Steirteghem A; Devroey P Hum Reprod; 1999 Jun; 14(6):1426-30. PubMed ID: 10357952 [TBL] [Abstract][Full Text] [Related]
10. Is there a difference in the function of granulosa-luteal cells in patients undergoing in-vitro fertilization either with gonadotrophin-releasing hormone agonist or gonadotrophin-releasing hormone antagonist? Lin Y; Kahn JA; Hillensjö T Hum Reprod; 1999 Apr; 14(4):885-8. PubMed ID: 10221213 [TBL] [Abstract][Full Text] [Related]
11. A prospective randomized comparison of routine buserelin acetate and a decreasing dosage of nafarelin acetate with a low-dose gonadotropin-releasing hormone agonist protocol for in vitro fertilization and intracytoplasmic sperm injection. Takeuchi S; Minoura H; Shibahara T; Tsuiki Y; Noritaka F; Toyoda N Fertil Steril; 2001 Sep; 76(3):532-7. PubMed ID: 11532477 [TBL] [Abstract][Full Text] [Related]
12. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639 [TBL] [Abstract][Full Text] [Related]
13. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study. Bodri D; Guillén JJ; Galindo A; Mataró D; Pujol A; Coll O Fertil Steril; 2009 Feb; 91(2):365-71. PubMed ID: 18367175 [TBL] [Abstract][Full Text] [Related]
14. Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist Cetrorelix. Tavaniotou A; Albano C; Smitz J; Devroey P Hum Reprod; 2001 Apr; 16(4):663-7. PubMed ID: 11278214 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness of cetrorelix for the prevention of premature luteinizing hormone surge during controlled ovarian stimulation using letrozole and gonadotropins: a randomized trial. Lee TH; Lin YH; Seow KM; Hwang JL; Tzeng CR; Yang YS Fertil Steril; 2008 Jul; 90(1):113-20. PubMed ID: 18054932 [TBL] [Abstract][Full Text] [Related]
16. Comparison of outcome of clomiphene citrate/human menopausal gonadotropin/cetrorelix protocol and buserelin long protocol--a randomized study. Lin YH; Hwang JL; Seow KM; Huang LW; Hsieh BC; Tzeng CR Gynecol Endocrinol; 2006 Jun; 22(6):297-302. PubMed ID: 16785154 [TBL] [Abstract][Full Text] [Related]
17. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol. Griesinger G; Schultze-Mosgau A; Dafopoulos K; Schroeder A; Schroer A; von Otte S; Hornung D; Diedrich K; Felberbaum R Hum Reprod; 2005 May; 20(5):1200-6. PubMed ID: 15665010 [TBL] [Abstract][Full Text] [Related]
18. GnRH agonist trigger with intensive luteal phase support vs. human chorionic gonadotropin trigger in high responders: an observational study reporting pregnancy outcomes and incidence of ovarian hyperstimulation syndrome. Christopoulos G; Vlismas A; Carby A; Lavery S; Trew G Hum Fertil (Camb); 2016 Sep; 19(3):199-206. PubMed ID: 27662416 [TBL] [Abstract][Full Text] [Related]
19. [Effects of cetrorelix versus ganirelix in gonadotropin-releasing hormone antagonist cycles for preventing premature luteinizing hormone surges and on clinical outcomes of IVF-ET cycles]. Zhang J; Zhou X; Chen Y; Zhang Q; Li Y; Zhe J; Chen X; Chen S Nan Fang Yi Ke Da Xue Xue Bao; 2019 Oct; 39(10):1207-1212. PubMed ID: 31801718 [TBL] [Abstract][Full Text] [Related]
20. The impact of LH serum concentration on the clinical outcome of IVF cycles in patients receiving two regimens of clomiphene citrate/gonadotrophin/0.25 mg cetrorelix. Tavaniotou A; Albano C; Van Steirteghem A; Devroey P Reprod Biomed Online; 2003 Jun; 6(4):421-6. PubMed ID: 12831586 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]